AU2003300414A1 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers - Google Patents
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomersInfo
- Publication number
- AU2003300414A1 AU2003300414A1 AU2003300414A AU2003300414A AU2003300414A1 AU 2003300414 A1 AU2003300414 A1 AU 2003300414A1 AU 2003300414 A AU2003300414 A AU 2003300414A AU 2003300414 A AU2003300414 A AU 2003300414A AU 2003300414 A1 AU2003300414 A1 AU 2003300414A1
- Authority
- AU
- Australia
- Prior art keywords
- bcl
- disorder
- treatment
- methods
- antisense oligomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43502902P | 2002-12-19 | 2002-12-19 | |
US43505702P | 2002-12-19 | 2002-12-19 | |
US60/435,029 | 2002-12-19 | ||
US60/435,057 | 2002-12-19 | ||
US10/738,717 US20040147473A1 (en) | 2000-11-10 | 2003-12-16 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US10/738,717 | 2003-12-16 | ||
US10/738,867 US7855183B2 (en) | 2000-11-10 | 2003-12-16 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US10/738,867 | 2003-12-16 | ||
PCT/US2003/041433 WO2004056971A2 (en) | 2002-12-19 | 2003-12-19 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003300414A8 AU2003300414A8 (en) | 2004-07-14 |
AU2003300414A1 true AU2003300414A1 (en) | 2004-07-14 |
Family
ID=32686284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003300414A Abandoned AU2003300414A1 (en) | 2002-12-19 | 2003-12-19 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003300414A1 (en) |
WO (1) | WO2004056971A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060018911A1 (en) * | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US7524827B2 (en) * | 2004-06-01 | 2009-04-28 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
ES2419106T3 (en) | 2005-12-01 | 2013-08-19 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
JP5623016B2 (en) * | 2005-12-01 | 2014-11-12 | プロネイ・セラピューティクス・インコーポレイテッドPronaitherapeutics, Inc. | Cancer therapy and pharmaceutical composition used therefor |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
WO2010043582A1 (en) * | 2008-10-17 | 2010-04-22 | Santaris Pharma A/S | Method for the treatment of cancer |
KR20150087270A (en) * | 2012-11-05 | 2015-07-29 | 프로나이 테라퓨틱스, 인코포레이티드 | Methods of using biomarkers for the treatment of cancer by modulation of bcl2 expression |
EP3319995B1 (en) | 2015-07-07 | 2019-04-17 | H. Hoffnabb-La Roche Ag | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor |
ES2965461T3 (en) | 2015-08-03 | 2024-04-15 | Biokine Therapeutics Ltd | CXCR4 inhibitor for cancer treatment |
WO2022067185A1 (en) * | 2020-09-27 | 2022-03-31 | Veru Inc. | Methods of treating prostate cancer with minimal side effects |
-
2003
- 2003-12-19 WO PCT/US2003/041433 patent/WO2004056971A2/en not_active Application Discontinuation
- 2003-12-19 AU AU2003300414A patent/AU2003300414A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004056971A3 (en) | 2005-03-10 |
AU2003300414A8 (en) | 2004-07-14 |
WO2004056971A2 (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU8837301A (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
WO2003101508A8 (en) | Wound treatment apparatus | |
AU2003280004A1 (en) | Hair treatment method | |
GB0512560D0 (en) | Bioreactors for well treatment | |
AU2002215125A1 (en) | Well treatment method | |
AU2002329570A1 (en) | Method of monitoring neuroprotective treatment | |
GB0129976D0 (en) | Treatment method | |
AU2003300414A1 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
HUP0400032A3 (en) | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg | |
IL161005A0 (en) | Neuroprotective treatment methods using selective inos inhibitors | |
GB0120147D0 (en) | Treatment method | |
GB0105899D0 (en) | Fibrosis reduction treatment | |
AUPR731901A0 (en) | Method of treatment | |
AU2001253560A1 (en) | Methods of treatment | |
AU2002101010A4 (en) | Treatment process and apparatus | |
GB0126253D0 (en) | Treatment method | |
GB2413798B (en) | Bioreactors for well treatment | |
AU2002367702A1 (en) | Entertainment and treatment method | |
AU2002222385A1 (en) | Diamond treatment | |
AUPR950401A0 (en) | Methods for treatment | |
AUPR082000A0 (en) | Treatment of bone disorder | |
AU2002240993A1 (en) | Apparatus for treatment of wastewater, including a biofilter and a post-filter | |
AU2002343791A1 (en) | Anaerobic treatment apparatus | |
AUPS164502A0 (en) | Treatment methods | |
AUPR508701A0 (en) | Improved wastewater treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |